INSM · INSMED Inc

Track INSM — free Ask ALVIS about INSM

$99.02 +0.27 (+0.27%) At close · Aug 5

Market Cap

$21.64B

216.75M

Up next

FQ3-26 quarter ends

~Sep 30, 2026 Est

Latest filing: 10-Q

filed May 7, 2026

AI Brief

TL;DR.

Bullish

Bearish

AI-generated from the earnings call and 8-K · may contain errors · not investment advice

Ask ALVIS about this →

Equibles Rating

blended score · not investment advice

Overall

Strong Sell

SellHoldBuy

Technical Strong Sell Momentum Very Weak Sentiment Bullish Fundamentals Poor Quant / Vol Very High

Market backdrop VIX 15.8 · calm Equity put/call 0.46

Technical

price trend

Strong Sell

50 / 200-day cross No cross

Price vs 200-day avg −32%

below

Price vs 50-day avg −5%

below

RSI (14) 36

neutral

MACD trend Negative

52-week position 7%

near low

Volume (OBV) Confirms

volume backs price

Momentum

relative strength

Very Weak

1-month return −15%

trailing

6-month return −33%

trailing

YTD return −43%

this year

Relative strength −45%

vs S&P · 6-mo

Sentiment

smart money

Bullish

Trend (MA cross) No cross

50d $104 › 200d $147 — 200d above 50d

Institutional flow Accumulating

252 of 675 funds reported for Jun 30 · net +442.9K sh shares · +35 new

Insider flow Distributing

Net -$13.0M over 90 days · 100% sells

Short interest Falling

5.36% of float · ▼ -27.5% MoM · 4.8 days cover

Volume signal Normal

Volume near normal

Institution breadth Multi-yr high

675 holders — near 3-yr high, broad support

Squeeze score 56

elevated · 0–100

Fundamentals

Poor

EPS growth −15%

Y/Y

Free cash flow $-967.6M

Balance sheet $33.6M

net debt

Quant / Vol

risk profile

Very High

Volatility 53%

annualized · 1-yr

Max drawdown −57%

past year

ATR 3.9%

of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

what management promised — and delivered

Latest guidance · from the 8-K filed May 7, 2026

BRINSUPRI revenues · full-year 2026 Initiated at least $1B

prior FY $606.42M midpoint +64.9% Y/Y

ARIKAYCE revenues · full-year 2026 Initiated $450M – $470M

prior FY $606.42M midpoint −24.1% Y/Y

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Strong Sell

4 · 3 · 0

50 / 200-day cross

No cross Neutral

Price vs 200-day avg

−32% Bearish

Price vs 50-day avg

−5% Bearish

RSI (14)

36 Neutral

MACD trend

Negative Bearish

52-week position

7% Bearish

Volume (OBV)

Confirms Neutral

Market signals — smart money & positioning

Bullish · 3 of 6

Trend (MA cross) No cross

50d $104 › 200d $147 — 200d above 50d

Institutional flow Accumulating

252 of 675 funds reported for Jun 30 · net +442.9K sh shares · +35 new

Insider flow Distributing

Net -$13.0M over 90 days · 100% sells

Short interest Falling

5.36% of float · ▼ -27.5% MoM · 4.8 days cover

Volume signal Normal

Volume near normal

Institution breadth Multi-yr high

675 holders — near 3-yr high, broad support

Price context

position in its 52-week range

52-wk low $90 Now $99 · 7% 52-wk high $213

vs 200-day avg -32% vs 50-day avg -5%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from its earnings releases, calls, and filings

Metric	Latest	Period	YoY
ARIKAYCE global revenue growth	6%	Q1 2026 vs Q1 2025	—
BRINSUPRI global revenue growth	44%	Q1 2026 vs Q4 2025	—

Figures exactly as the company stated them · click a metric with a to chart its history · period links open the stating document · "call" marks figures stated on the earnings call, "filing" figures stated in the 10-K/10-Q · YoY needs the prior-year figure on file

Versus peers

Biotechnology — same industry group

Open screener →

Company	Mkt cap	YTD	Rev growth Y/Y	P/E	Short % shares
INSM INSMED Inc this stock	$21.64B	-43.1%	+66.7%	—	5.4%
ONC BeOne Medicines Ltd.	$453.48B	+7.8%	+22179.2%	697.3	0.1%
VRTX Vertex Pharmaceuticals Inc / Ma	$119.47B	+6.9%	+46.2%	27.5	2.0%
REGN Regeneron Pharmaceuticals, Inc.	$78.17B	-0.2%	+20.8%	18.8	3.4%
ARGX Argenx SE	$54.30B	+3.2%	—	—	2.5%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section

Ownership

Institutional Holders Accumulating

Holders

670

% held: 96.8%
Reported: 252 of 675
Top holder: JPMORGAN CHASE & CO

Held Float

View

Held by Funds

Fund positions

723

View

Short & Settlement

Short Interest Falling

Shares short

11.6M

Days to cover: 4.8d
Change: -4.4M sh

View

Short Volume

Short vol %

17%

As of: Aug 5, 2026

Short Total

View

Fails to Deliver

FTD shares

9.2K

Value: $1.1M
As of: Jul 13, 2026

View

Off-Exchange

Off-exchange %

47.9%

Week of: Jul 6, 2026

Off-exch Lit

View

Smart Money

Insider Trades Net selling

Net (90d)

-$13.0M

Buyers / Sellers: 0 / 5

Buyers Sellers

View

Congressional Trades Sell

Member

Josh Gottheimer

Amount: $1.0K–$15.0K
Traded: Jun 10, 2026

View

Financials

Revenue (FY)

$606.4M

Net income (FY): $-1.3B
EPS diluted: $-6.42

View

Filings

SEC Filings

Latest

8-K

Filed: Jul 16, 2026
This year: 11

View

Proposed Sales

Value

$1.7M

Shares: 10.7K
Filed: Apr 6, 2026

View

Earnings & Events

Earnings Calls

Last call

Jun 9, 2026

View

Performance

	5D	20D	120D	MTD	YTD
INSM	-4.0%	-15.0%	-33.3%	+0.4%	-43.1%
SPY	+5.5%	+3.3%	+11.3%	+3.1%	+12.9%
vs SPY	-9.5%	-18.3%	-44.5%	-2.6%	-56.0%

Key facts CIK 1104506 CUSIP 457669307 13F (30d) 210 filings 206 filers Visit website Investor relations

INSM · INSMED Inc

Price & Indicators

Up next

AI Brief

Equibles Rating

Guidance & track record

Technicals

Key metrics

Versus peers

At a glance

Performance